SRPT Stock: Price, Earnings History and SEC Filings
Sarepta Therapeutics, Inc. (SRPT) last traded at $18.62, down 3.17% on the latest session and up 2.2% over the past month. In its most recent reported quarter (Jun 2026) earnings per share were $0.42 against an analyst estimate of $0.34, a beat of 23.5%.
$18.62 -3.17%
1 month+2.20%
52-week high$24.68
52-week low$14.68
Volume1.32M
ExchangeNasdaqGS
Price data from Yahoo Finance, as of Oct 30, 2026. May be delayed.
SRPT earnings history
| Quarter | Reported | EPS | Estimate | Surprise |
|---|---|---|---|---|
| Jun 2026 | Aug 5, 2026 | $0.42 | $0.34 | +23.53% |
| Mar 2026 | May 6, 2026 | $3.09 | $0.39 | +692.31% |
| Dec 2025 | Feb 25, 2026 | $-3.87 | $-1.03 | -275.73% |
| Sep 2025 | Nov 3, 2025 | $-0.28 | $-0.37 | +24.32% |
SRPT beat the analyst EPS estimate in 3 of its last 4 reported quarters. Source: Nasdaq.
Latest SEC filings for SRPT
SEC filing data is not available right now. You can search for SRPT on SEC EDGAR.
SRPT news
- Ultragenyx (RARE) vs. SRPT and BMRN: Can Upcoming Drug Approvals Unlock the Next Phase of Biotech Growth?Oct 30, 2026 · finance.yahoo.com
- Sarepta Therapeutics (SRPT) Earnings Preview Puts Its Fair Value Back In FocusOct 30, 2026 · finance.yahoo.com
- Next-Generation Adeno-Associated Virus (AAV) Gene Therapy Delivery Market Report 2026 | Capitalize on $11.91B Market as Novartis, Voyager and Affinia Accelerate Engineered CapsidsOct 30, 2026 · finance.yahoo.com
- Global Gene Silencing Therapeutics Market Report 2026-2030 | Capitalize on 16.3% CAGR as Novartis, Alnylam, Ionis, Sarepta, and Arrowhead Accelerate RNA DeliveryOct 30, 2026 · finance.yahoo.com
- Sarepta Therapeutics (SRPT) Earnings Expected to Grow: Should You Buy?Oct 29, 2026 · finance.yahoo.com
- Was The Run In Moderna Stock Hiding In Plain Sight?Oct 28, 2026 · trefis.com
- Has The Story Under Krystal Biotech Stock Run Out?Oct 28, 2026 · trefis.com
- Sarepta Therapeutics to Present at Upcoming Investor ConferencesOct 26, 2026 · finance.yahoo.com
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc. (SRPT) is a US-listed public company on Nasdaq.